Search tips
Search criteria 


Logo of neuroncolAboutAuthor GuidelinesEditorial BoardNeuro-Oncology
Neuro-oncol. 2006 April; 8(2): 145–155.
PMCID: PMC1871937

Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors


Genes involved in phase I and phase II regulation of aromatic hydrocarbon–induced effects exhibit sequence variability that may mediate the risk of adult brain tumors. We evaluated associations between gene variants in CYP1A1, CYP1B1, GSTM3, EPHX1, and NQO1 and adult brain tumor incidence. Cases were patients with glioma (n = 489), meningioma (n = 197), or acoustic neuroma (n = 96) diagnosed from 1994 to 1998 at three U.S. hospitals. Controls were 799 patients admitted to the same hospitals for nonmalignant conditions. DNA was extracted from blood samples collected from 1277 subjects, and genotyping was conducted for CYP1A1 I462V, CYP1B1 V432L, EPHX1 Y113H, GSTM3 *A/*B (intron 6 deletion), and NQO1 P187S. The CYP1B1 V432L homozygous variant was associated with decreased risk of meningioma (odds ratio [OR] = 0.6; 95% CI, 0.3–1.0) but not the other tumor types. The GSTM3 *B/*B genotype was associated with increased risk of glioma (OR = 2.3; 95% CI, 1.0–5.2) and meningioma (OR = 3.6; 95% CI, 1.3–9.8). Increased risks associated with GSTM3 *B/*B were observed in younger subjects (age <50) and older subjects (age [gt-or-equal, slanted]50), in men and women, and within each study site. The magnitude of association for GSTM3 with glioma and meningioma was greater among ever-smokers than among those who had never smoked. None of the other genotypes showed consistent associations with any tumor type. The association with the GSTM3 *B allele, while intriguing, requires replication, and additional research is needed to clarify the function of the GSTM3 alleles studied here.

Keywords: acoustic neuroma, aromatic hydrocarbons, brain tumors, gene-environment interaction, glioma, meningioma

Both genetic and environmental factors are likely to be important causes of primary brain tumors. The few clues about brain tumor etiology indicate that certain occupations involving exposure to polycyclic aromatic hydrocarbons (PAHs)2 or other aromatic hydrocarbons may be associated with increased risk (Inskip, P.D., et al., 1995), most notably work in the petroleum industry (Carozza et al., 2000; Demers et al., 1991; Preston-Martin, 1989; Thomas et al., 1986, 1987); however, multiple exposures in implicated occupations limit possible conclusions about aromatic hydrocarbons. Smoking, a major source of aromatic hydrocarbon exposure, has been associated with brain tumor incidence in several studies (Burch et al., 1987; Lee et al., 1997), but not consistently so (Inskip, P.D., et al., 1995), and sometimes only among certain subgroups (Efird et al., 2004; Phillips et al., 2005). It is possible that underlying variability in genes responsible for biotransformation and metabolism of aromatic hydrocarbons could hinder the consistency of studies of chemical exposures. For this reason, it may be illuminating to study the association of variants in genes involved in aromatic hydrocarbon metabolism with the risk of brain tumors.

The conversion of PAHs to DNA-reactive products depends on a complex series of biotransformations. In the case of benzo[a]pyrene, transformation events include oxidation by cytochrome P-450 enzymes (such as CYP1A1) to create the active benzo[a]pyrene epoxide (Pelkonen and Nebert, 1982; Shimada et al., 1996), hydration by microsomal epoxide hydrolase (EPHX1) to the less toxic benzo[a]pyrene diol, oxidation by P-450 enzymes (such as CYP1B1) to the highly carcinogenic benzo[a]pyrene diol epoxide, detoxification of benzo[a]-pyrene and benzo[a]pyrene diol epoxide by glutathione S-transferases (such as GSTM1, GSTT1, and possibly GSTM3) by addition of reduced glutathione to electrophilic compounds (Omiecinski et al., 2000; Strange et al., 2001), and reduction of oxidative potential of quinones derived from benzo[a]pyrene diol by NAD(P)H:quinone oxidoreductase 1 (NQO1) (Palackal et al., 2002; Pastorelli et al., 1998; Ross et al., 2000). There is evidence from animal experiments that NAD(P)H protects from PAH-induced carcinogenicity; this protection is thought to operate through decreases in quinone-induced DNA adduct formation and DNA mutagenicity, including that induced by benzo[a]pyrene quinine (Joseph and Jaiswal, 1998; Long et al., 2001).

In a previous report, we presented case-control study results for some genes known to be involved in metabolism of PAHs or other potential carcinogens, namely, CYP2E1, GSTM1, and GSTT1 (De Roos et al., 2003). For the current investigation, we selected several additional candidate genes related to PAHs or other aromatic hydrocarbons; all of the selected metabolic genes exhibit sequence variation that may relate to function. Substitution of valine with isoleucine in exon 7 of CYP1A1 results in a variant (I462V) with increased arylhydrocarbon hydroxylase activity (Cosma et al., 1993; Crofts et al., 1994; Kiyohara et al., 1996, 1998; Taioli et al., 1995). The functional significance of a CYP1B1 variant, V432L, is not well known; however, some studies suggest that the valine product results in higher catalytic activity toward some PAH dihydrodiols relative to leucine (Shimada et al., 1999), possibly leading to increased levels of reactive intermediates. The GSTM3 gene has a three-base-pair deletion in intron 6, and the two alleles are referred to as GSTM3*A and GSTM3*B (Inskip, A., et al., 1995; Strange et al., 2001). This deletion creates a recognition motif (-aagata-) for the YY1 transcription factor which could potentially affect detoxification activity by GSTM3*B (Strange et al., 2001). The EPHX1 variant Y113H has demonstrated increased activity in vitro but not in vivo (Hassett et al., 1994; Omiecinski et al., 2000). In vitro, EPHX1 activity is increased (about 40%) when associated with the histidine product, probably because of altered protein stability (Hassett et al., 1994). The NQO1 P187S variant resulting from C-to-T substitution leads to reduced enzyme function (Moran et al., 1999; Traver et al., 1997) and thus, presumably, less protection against oxidative damage.

We examined the effects of these metabolic gene variants in a parallel comparison of three major categories of malignant and benign brain tumors, namely the gliomas, meningiomas, and acoustic neuromas. Although we selected genes according to their possible relevance to metabolism of PAHs and other aromatic hydrocarbons, the substrate specificity is quite broad, and it is unclear to what extent the selected genes reflect a coherent pathway. Nevertheless, this exploratory approach was considered appropriate, given the dearth of knowledge about causes of brain tumors.

Material and Methods

Study Population

The study has been described in detail elsewhere (Inskip et al., 2001). Eligible cases were adult patients with intracranial tumors including glioma, meningioma, or acoustic neuroma (referred to as brain tumors in this article), newly diagnosed from 1994 to 1998 and treated at one of three participating U.S. hospitals located in Phoenix, Ariz., Boston, Mass., and Pittsburgh, Pa. We sought approval of physicians to contact newly diagnosed brain tumor patients for recruitment into the study. We enrolled 489 glioma, 197 meningioma, and 96 acoustic neuroma patients, for a total of 782 cases of malignant or benign brain tumors, representing 92% of those contacted (88% for glioma; 98% for meningioma and acoustic neuroma). Information on tumor pathology was based on the diagnosis from each hospital. Gliomas were classified as low grade or high grade according to Kleihues and Cavenee (2000).

Controls were patients admitted to the same hospitals and treated for a variety of nonneoplastic conditions. They were frequency-matched to the total case series by hospital, age, gender, race, and proximity of residence to hospital. Of the eligible controls identified and asked to participate, 799 control subjects were recruited, representing 86% of those contacted. Discharge diagnoses of the control subjects were trauma, injury, or poisoning (24.7%), circulatory disease (22.4%), musculoskeletal disease (21.5%), disease of the digestive system (11.5%), and other (19.9%).

Trained nurses conducted a structured, computerized, in-person interview that included detailed questions on the following: lifetime job history; specific occupational exposures, processes, and tasks; hobbies involving solvent exposures; cellular telephones and other forms of communication devices; medical history; exposure to diagnostic and therapeutic radiation; reproductive history and use of exogenous hormones; use of hair dyes; family history of cancer and selected other conditions; and sociodemographic characteristics. A supplemental self-administered questionnaire addressed diet, vitamin supplements, and electric appliances.

Laboratory Analyses

DNA was extracted from peripheral white blood cells (buffy coat or granulocytes) from blood samples collected from 1277 subjects (81% of all subjects; 422 gliomas [86%], 172 meningiomas [87%], 79 acoustic neuromas [82%], and 604 controls [76%]), by GenoType, Ltd. (United Kingdom) using a phenol-chloroform method as described by Daly et al. (1996). The percentage of potentially eligible subjects who provided both interview data and blood samples was 76% for glioma, 85% for meningioma, 80% for acoustic neuroma, and 65% for controls.

Genotyping was conducted by the NCI Core Genotyping Facility (Gaithersburg, Md.). CYP1A1 I462V was genotyped by using an MGB Eclipse (Epoch Biosciences, Bothell, Wash.) reaction method. For this, 10 ng of lyophilized sample DNA was used to do a 5-μl MGB Eclipse reaction in a 384 (96*4)-well plate format as described elsewhere (, except 10 ng of DNA was used. The SDS software (Applied Bio-systems, Foster City, Calif.) displays the results of allelic discrimination run in a dissociation curve format. The dissociation curve is exported in text format for further analysis by using the MGB Eclipse software as described by Belousov et al. (2004).

CYP1B1 L432V, EPHX1 Y113H, GSTM3 *A or *B, and NQO1 P187S were genotyped by using TaqMan (Applied Biosystems) methods. In this procedure, 5 ng of lyophilized sample DNA was used to do a 5-μl TaqMan reaction in a 384 (96*4)-well plate format as described elsewhere (see the TaqMan assays at

Quality-control (QC) measures included the addition of replicates (62 samples from three individuals who were not study subjects [QC-A, n = 31; QC-B, n = 18; QC-C, n = 13], collected and processed in identical fashion as samples from study subjects) and duplicates (two samples for each of 87 individuals who were study subjects) interspersed throughout the batches for all assays. Assay-specific positive controls for the three possible genotypes were included on each assay plate.

Statistical Analyses

SAS software version 9.1 (SAS Institute Inc., Cary, N.C.) was used for all statistical analyses. We calculated chi-squared statistics to test Hardy–Weinberg equilibrium of each genotype among the control group to determine whether the distribution of alleles was as expected (Hernandez and Weir, 1989).

The effect of each gene variant on the incidence of each brain tumor type, with the homozygous common genotype as the referent, was estimated by conventional maximum likelihood using unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence limits. All effect estimates for gene variants were adjusted for the study by matching factors of age (coded in years: 18–29, 30–39 as the referent, 40–49, 50–59, 60–69, 70–79, or 80–90), race/ethnicity (non-Hispanic white as the referent, Hispanic white, black, or other), gender (male, female as the referent), hospital (Phoenix as the referent, Boston, or Pittsburgh), and proximity of patient’s residence to the hospital (coded in miles: 0–4 as the referent, 5–14, 15–29, 30–49, or [gt-or-equal, slanted]50). We checked the influence of the control series composition on results by examining the consistency of the effect of each genotype on each tumor type, while excluding one major category of control discharge diagnoses at a time.

We conducted subgroup analyses to examine whether associations with each gene variant differed by age group (<50 years, [gt-or-equal, slanted]50 years), gender, study site (Phoenix, Boston, Pittsburgh), or smoking status (ever, never). Other factors of interest, such as race and family history of nervous system tumors, did not have sufficient numbers within groups to enable subgroup analyses. We also examined the association of each gene variant with high-grade and low-grade glioma, and with specific glioma subtypes including glioblastoma, anaplastic astrocytoma, other astrocytoma, oligodendroglioma, and mixed oligoastrocytoma; these analyses included all controls. Chi-squared statistics and corresponding P values (based on 4 degrees of freedom) were calculated to test whether the distribution of each gene variant differed among the five glioma subtypes. For subgroup analyses and subanalyses by tumor type, we calculated the risk associated with the homozygous variant (where numbers allowed or where an association appeared to occur primarily for the homozygous variant) or the combined heterozygous–homozygous variant genotypes. The homozygous common genotype was always used as the referent.

We tested for interaction between polymorphisms in several putative activating enzymes (phase I) and detoxification enzymes (phase II); in other words, we tested whether the presence of two variant alleles in these genes imparted increased risk that was greater than multiplicative of the risk associated with either variant alone. Interactions between metabolic genes (from this study and our previous report [De Roos et al., 2003]) were examined for specific combinations indicated by function or epidemiologic data as potentially interactive in the context of aromatic hydrocarbon metabolism. We investigated combinations of CYP1A1 I462V and GSTM1 null because of reports of interaction between these genotypes in the risk of several types of cancer (Hung et al., 2003; London et al., 2000; Murata et al., 1998, 2001; Nimura et al., 1997; Olshan et al., 2000; Sato et al., 2000; Stucker et al., 2000; Wang et al., 2002), GSTM3 *A/*B and GSTM1 null because of possible interaction of these genes reported for various cancers (Loktionov et al., 2001; Yengi et al., 1996), EPHX1 Y113H, and GSTM1 null because interaction was previously observed in a study of orolaryngeal cancer (Park et al., 2003), and NQO1 P187S and CYP2E1*5 (RsaI) because these genes are dually involved in quinone metabolism (Nebert et al., 2002). Each combination was examined by including indicator variables for the two individual-variant effects and one joint-variant effect in a logistic regression model with the matching factor variables, and interaction on the multiplicative scale was tested in a separate logistic regression model using the P value for an interaction term.


Demographic characteristics of cases and controls are presented in Table 1. Frequency matching ensured comparability of cases and controls in the study with respect to race. Patients with brain tumors were, on average, older and more highly educated than controls. Meningioma patients were more often female as compared to controls or patients with other tumor types. A greater proportion of acoustic neuroma cases were from the Phoenix study site, as compared to the other tumor types or controls. Controls were more likely than patients with brain tumors to live in closer proximity to the hospital.

Table 1
Frequencies of characteristics of brain tumor cases and controls from three U.S. hospitals (1994–1998)

Genotyping was successfully conducted for CYP1A1 I462V (98.1% of all study samples analyzed), CYP1B1 V432L (95.9%), EPHX1 Y113H (97.3%), GSTM3 *A/*B (97.0%), and NQO1 P187S (91.7%), and genotyping of all five variants was successful for 76.9% of the samples analyzed for all five genotypes. Missing values, primarily the result of insufficient quantity of high-quality DNA or poor amplification for a specific locus, were equally likely to be from case or control samples. We achieved 97% to 100% agreement among replicates for all assays and 93% to 98% agreement between duplicate samples for all assays according to the kappa statistic. The frequencies of the rare alleles for CYP1A1 I462V, CYP1B1 V432L, EPHX1 Y113H, GSTM3 *A/*B, and NQO1 P187S (Table 2) were similar to those in other study populations (Chang et al., 2003; Garte et al., 2001; Kelsey et al., 1997; Strange et al., 2001). There was no evidence of departure from Hardy–Weinberg equilibrium for any genotype.

Table 2
Gene variant associations with brain tumor incidence (OR and 95% CI)a

GSTM3 *B/*B genotype was associated with increased risk of both glioma and meningioma, with moderate associations for the *B/*B genotype versus *A/*A (glioma: OR = 2.3; 95% CI, 1.0–5.2; and meningioma: OR = 3.6; 95% CI, 1.3–9.8) (Table 2). None of the acoustic neuroma cases were GSTM3 *B/*B genotype; however, the heterozygous genotype gave no indication of any association between GSTM3 and acoustic neuroma (OR = 1.1; 95% CI, 0.6–1.9). CYP1B1 432 Val/Val was inversely associated with meningioma (OR = 0.6; 95% CI, 0.3–1.0), although there was no dose–response relationship according to the number of variant alleles. EPHX1 113 His/His was associated with slightly increased risks of all three tumor types (ORs = 1.5) that were not statistically significant. Neither the CYP1A1 I462V nor the NQO1 P187S variant was associated with the risk of any brain tumor type.

Although data were sparse in subgroup analyses (Table 3), the positive association of the GSTM3 *B/*B genotype with glioma and meningioma was present within different age groups and in both genders. The magnitude of association of GSTM3 *B/*B with glioma and meningioma was greater among ever-smokers than never-smokers, and the interaction between GSTM3 and smoking was statistically significant for meningioma; nevertheless, ORs for the variant genotype were elevated among nonsmokers as well. The GSTM3 *B/*B genotype was associated with both low-grade and high-grade tumors (results not shown in the tables, ORs = 1.8 and 2.3, respectively), and with all subtypes of glioma except anaplastic astrocytoma (ORs range from 1.8 to 3.8, none statistically significant; not shown in the tables). Increased risk associated with GSTM3 *B/*B was similar across the three study sites, as well as in all subanalyses testing the sensitivity of results to exclusions from the control series (results not shown). The subgroup analyses of CYP1B1 V432L with meningioma did not reveal any particular group with decreased risk associated with the homozygous variant genotype, as results were fairly uniform across groups of age, gender, and smoking status. For glioma, EPHX1 113 His/His was associated with increased risk primarily among subjects 50 years or older, women, and ever-smokers. These patterns were less clear for meningioma and acoustic neuroma. Although no overall association was observed with the variant P187S variant, the subgroup analysis suggested that variant genotype might be associated with increased glioma and acoustic neuroma risk among men and among those who had ever smoked.

Table 3
Gene variant associations with brain tumor incidence, subgroup analyses (OR and 95% CI)a,b

There was some indication of positive interaction between CYP2E1*5 (RsaI) and NQO1 P187S variants in the risk of glioma or acoustic neuroma (Table 4). Individuals with the combination of increased CYP2E1 activity (CYP2E1*1A/CYP2E1*5 or CYP2E1*5/CYP2E1*5) and reduced NQO1 activity (carriers of NQO1 187 Ser) were at approximately threefold increased risk of glioma and fourfold increased risk of acoustic neuroma. This interaction was of borderline statistical significance (P = 0.05) for glioma, but not for acoustic neuroma because of small numbers. This potential interaction was not observed for meningioma. There was no evidence of interactions between CYP1A1 I462V and GSTM1 null, between GSTM3 *A/*B and GSTM1 null, or between EPHX1 Y113H and GSTM1 null for any tumor type (results not shown).

Table 4
Combined gene variant associations with brain tumor incidence (OR and 95% CI)a


Of the gene variants we studied, only GSTM3 *A/*B (intron 6 deletion) showed noteworthy patterns of association with adult brain tumors, specifically glioma and meningioma. GSTM3 is expressed in astrocytes, and strong expression has been observed at the boundary between astrocytes and tumor cells (Hand et al., 1996). The associations we observed were quite consistent across different age groups, genders, and study sites. Both low-grade and high-grade gliomas were associated with the GSTM3 *B allele, as were all glioma subtypes except anaplastic astrocytoma. The fact that we observed a positive association for both glioma and meningioma suggests a common risk factor for the two tumor types that could be metabolized by GSTM3. The observation of a stronger magnitude of association among those who had ever smoked suggests a biologic pathway relevant to metabolism of components of cigarette smoke, such as PAHs. However, our results differ from what has been reported in the literature. A previous study found no association between GSTM3 polymorphism and the risk of astrocytoma (Hand et al., 1996). Initial suppositions about the functional activity of the GSTM3 *A and *B alleles suggest that increased risk should be associated with the *A/*A genotype rather than the *B/*B genotype (Inskip, A., et al., 1995). In support of this, epidemiologic studies have found that the *B/*B genotype was inversely associated with cancer risk, including basal cell carcinoma (Yengi et al., 1996), laryngeal cancer (Matthias et al., 1998), and oral and pharyngeal cancers (Jahnke et al., 1997; Park et al., 2000). Nevertheless, some researchers have observed increased cancer risk associated with the GSTM3 *B allele for bladder cancer (Schnakenberg et al., 2000), colorectal cancer (Loktionov et al., 2001), and nonmelanoma skin cancer in renal transplant patients (Ramsay et al., 2001). Unfortunately, little is known about chemical substrates that might be specific to GSTM3 and not GSTM1. The GSTM3 *B allele creates a new YY1 binding site, and this ubiquitous transcriptional regulator can act as a negative-acting or positive-acting factor, according to the system, which could potentially explain differing directions of association among cancer sites. Beuckmann et al. (2000) report that human GSTM3 may act as a prostaglandin E2 synthase in the brain, and if true, this suggests a possible mechanism involving growth regulation. However, because of the relatively low frequency of the *B/*B genotype, findings in epidemiologic studies may be due to chance.

There have been very few studies of the other gene variants that we examined in relation to adult brain tumors. Null results similar to ours have previously been reported for associations of glioma incidence with CYP1A1 I462V (Trizna et al., 1998) and NQO1 P187S (Peters et al., 2001). Our data indicate that these genotypes are also not associated with the risk of meningioma or acoustic neuroma. However, there was some indication that NQO1 might interact with other genes that are involved in quinone metabolism, namely, CYP2E1 RsaI. In our previous research on metabolic gene variants and the risk of adult brain tumors (De Roos et al., 2003), there were modest associations of CYP2E1 RsaI and GSTP1 I105V variant genotypes with increased glioma and acoustic neuroma incidence, and there was some indication of a positive interaction between the gene variants for those tumor types. Results from the current study further underscore the potential importance of multiple gene variants of various biologic pathways in carcinogenesis.

There have been no previous studies of the CYP1B1 V432L variant in association with brain tumors; our data showed an inverse association of the variant with meningioma only. Given the increased catalytic activity of the valine product, which produces a toxic intermediate, we would have expected increased risk associated with the variant for a biologic pathway relevant to aromatic hydrocarbons. CYP1B1 is also involved in steroid hormone metabolism, however, and lower levels of estradiol have been observed among women with the valine product (De Vivo et al., 2002; Garcia-Closas et al., 2002). The valine product has been associated with increased risks of ovarian cancer (Goodman et al., 2001) and estrogen-receptor-positive breast cancer (Bailey et al., 1998) and, conversely, with decreased risk of breast cancer in a study of Asian women (Zheng et al., 2000). Risk factors for meningioma include various hormone-related factors such as gender and parity (Inskip, P.D., et al., 1995), and it is possible that the relevance of the observed association with CYP1B1 V432L is through an effect on endogenous hormones, although the mechanisms are unclear. Nevertheless, the association between the CYP1B1 variant and meningioma was similar in men and women, which detracts from the evidence for a hormone-related pathway explaining the gene variant’s association with brain tumors.

The results for EPHX1 Y113H were suggestive of associations within certain subgroups. A slightly increased risk associated with EPHX1 113 His/His for glioma was predominated by elevated risks among older subjects (age > 50), women, and ever-smokers. The patterns were less clear for meningioma and acoustic neuroma. The fact that a slight increased risk appears for all three tumor types suggests the possibility of an unusual genotype distribution among the control group. However, we found similar results upon examination of differing compositions of the control group (ORs ranging from 1.2 to 1.7 for glioma in analyses excluding one control discharge diagnosis group at a time). In the context of PAH exposure, we would hypothesize increased risk of cancer associated with the lower predicted activity of the His/His protein product; nevertheless, EPHX1 high-activity alleles have been associated in some studies with increased risk for various types of cancer (Lancaster et al., 1996; Lee et al., 2002; Park et al., 2003; Wang et al., 2003), which suggests that these gene variants may play a more complex role in human carcinogenesis. The coding region substitution we studied accounts for only a fraction of all variation in human microsomal epoxide hydrolase activity (Hassett et al., 1997; Raaka et al., 1998). Another known variant at codon 139 (H139R) has been observed in vitro to increase EPHX1 enzyme activity by approximately 25% (for the 139 arginine protein), and additional genetic variants, possibly in regulatory regions of the EPHX1 gene, may also play a role (Hassett et al., 1997; Omiecinski et al., 2000).

These results add to the literature about the contribution of variation in metabolic genes to adult brain tumor incidence. Overall, these data do not provide strong evidence for the consistent importance of genes involved in biotransformation of PAHs and their metabolites for brain carcinogenesis; however, specific genes may play a role in the context of both PAHs and other exposures. Our observation of a positive association of GSTM3 *B/*B genotype with increased risk of glioma and meningioma, while intriguing, requires replication. Null results for other genotypes do not rule out possible interactions of the gene variants with relevant substrates, or with other genes involved in brain carcinogenesis. For example, our data indicate that NQO1 might interact with other genes that are involved in benzene metabolism, such as CYP2E1. Future analyses in our study will focus on detailed examination of genotype– exposure interactions for targeted occupational exposures of interest, including PAHs and other aromatic hydrocarbons.


This research was supported in part by the Intramural Research Program of the NIH, Division of Cancer Epidemiology and Genetics, National Cancer Institute.


2Abbreviations used are as follows: CYP, cytochrome P-450; DNA, deoxyribonucleic acid; EPHX, epoxide hydrolase; GST, glutathione S-transferase; NQO, NAD(P)H:quinone oxidoreductase; OR, odds ratio; PAH, polycyclic aromatic hydrocarbon; QC, quality control.


  • Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer (erratum in Cancer Res. [1999] 59, 1388) Cancer Res. 1998;58:5038–5041. [PubMed]
  • Belousov YS, Welch RA, Sanders S, Mills A, Kulchenko A, Dempcy R, Afonina IA, Walburger DK, Glaser CL, Yadavalli S, Vermeulen NM, Mahoney W. Single nucleotide polymorphism genotyping by two colour melting curve analysis using the MGB Eclipse Probe System in challenging sequence environment. Hum Genomics. 2004;1:209–217. [PubMed]
  • Beuckmann CT, Fujimori K, Urade Y, Hayaishi O. Identification of mu-class glutathione transferases M2-2 and M3-3 as cytosolic prostaglandin E synthases in the human brain. Neurochem Res. 2000;25:733–738. [PubMed]
  • Burch JD, Craib KJ, Choi BC, Miller AB, Risch HA, Howe GR. An exploratory case-control study of brain tumors in adults. J Natl Cancer Inst. 1987;78:601–609. [PubMed]
  • Carozza SE, Wrensch M, Miike R, Newman B, Olshan AF, Savitz DA, Yost M, Lee M. Occupation and adult gliomas. Am J Epidemiol. 2000;152:838–846. [PubMed]
  • Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J. Polymorphisms in the CYP1B1gene are associated with increased risk of prostate cancer. Br J Cancer. 2003;89:1524–1529. [PMC free article] [PubMed]
  • Cosma G, Crofts F, Taioli E, Toniolo P, Garte S. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health. 1993;40:309–316. [PubMed]
  • Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 1994;15:2961–2963. [PubMed]
  • Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol. 1996;272:199–210. [PubMed]
  • Demers PA, Vaughan TL, Schommer RR. Occupation, socioeconomic status, and brain tumor mortality: A death certificate-based case-control study. J Occup Med. 1991;33:1001–1006. [PubMed]
  • De Roos AJ, Rothman N, Inskip PD, Linet MS, Shapiro WR, Selker RG, Fine HA, Black PM, Pittman GS, Bell DA. Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev. 2003;12:14–22. [PubMed]
  • De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:489–492. [PubMed]
  • Efird JT, Friedman GD, Sidney S, Klatsky A, Habel LA, Udaltsova NV, Van den Eeden S, Nelson LM. The risk for malignant primary adult-onset glioma in a large, multiethnic, managed-care cohort: Cigarette smoking and other lifestyle behaviors. J Neurooncol. 2004;68:57–69. [PubMed]
  • Garcia-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer. 2002;102:172–178. [PubMed]
  • Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell’Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239–1248. [PubMed]
  • Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, Guo C, Le Marchand L. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev. 2001;10:209–216. [PubMed]
  • Hand PA, Inskip A, Gilford J, Alldersea J, Elexpuru-Camiruaga J, Hayes JD, Jones PW, Strange RC, Fryer AA. Allelism at the glutathione S-transferase GSTM3 locus: Interactions with GSTM1 and GSTT1 as risk factors for astrocytoma. Carcinogenesis. 1996;17:1919–1922. [PubMed]
  • Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants (erratum in Hum. Mol. Genet. [1994] 3, 1214) Hum Mol Genet. 1994;3:421–428. [PubMed]
  • Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. Human hepatic microsomal epoxide hydrolase: Comparative analysis of polymorphic expression. Arch Biochem Biophys. 1997;337:275–283. [PubMed]
  • Hernandez JL, Weir BS. A disequilibrium coefficient approach to Hardy-Weinberg testing. Biometrics. 1989;45:53–70. [PubMed]
  • Hung RJ, Boffetta P, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Garte S, Haugen A, Hirvonen A, Anttila S, Kalina I, Le Marchand L, London SJ, Rannug A, Romkes M, Salagovic J, Schoket B, Gaspari L, Taioli E. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: A pooled analysis. Carcinogenesis. 2003;24:875–882. [PubMed]
  • Inskip A, Elexperu-Camiruaga J, Buxton N, Dias PS, MacIntosh J, Campbell D, Jones PW, Yengi L, Talbot JA, Strange RC, Fryer AA. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: Evidence for linkage with GSTM1*A. Biochem J. 1995;312 (Pt 3):713–716. [PubMed]
  • Inskip PD, Linet MS, Heineman EF. Etiology of brain tumors in adults. Epidemiol Rev. 1995;17:382–414. [PubMed]
  • Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG, Fine HA, Black PM, Loeffler JS, Linet MS. Cellular-telephone use and brain tumors. N Engl J Med. 2001;344:79–86. [PubMed]
  • Jahnke V, Strange R, Matthias C, Fryer A. Glutathione S-transferase and cytochrome P450 genotypes as risk factors for laryngeal carcinoma. Eur Arch Otorhinolaryngol. 1997;254 (suppl. 1):S147–S149. [PubMed]
  • Joseph P, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones. Br J Cancer. 1998;77:709–719. [PMC free article] [PubMed]
  • Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, Wang M, Xu X, Lee BK, Schwartz BS, Wiencke JK. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76:852–854. [PMC free article] [PubMed]
  • Kiyohara C, Hirohata T, Inutsuka S. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res. 1996;87:18–24. [PubMed]
  • Kiyohara C, Nakanishi Y, Inutsuka S, Takayama K, Hara N, Motohiro A, Tanaka K, Kono S, Hirohata T. The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics. 1998;8:315–323. [PubMed]
  • Kleihues, P., and Cavenee, W.K. (Eds.) (2000) Pathology and Genetics of Tumours of the Nervous System Lyon, France: International Agency for Research on Cancer.
  • Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog. 1996;17:160–162. [PubMed]
  • Lee M, Wrensch M, Miike R. Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA) Cancer Causes Control. 1997;8:13–24. [PubMed]
  • Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, Rannug A, To-Figueras J, Ingelman-Sundberg M, Shields P, Gaspari L, Taioli E. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: A quantitative review. Biomarkers. 2002;7:230–241. [PubMed]
  • Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, Bingham SA. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: Interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis. 2001;22:1053–1060. [PubMed]
  • London SJ, Yuan JM, Coetzee GA, Gao YT, Ross RK, Yu MC. CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2000;9:987–991. [PubMed]
  • Long DJ, 2nd Waikel, R.L. Wang, X.J. Roop, D.R. and, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst. 2001;93:1166–1170. [PubMed]
  • Matthias C, Bockmuhl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, Gilford J, Bailey L, Bath J, Worrall SF, Hand P, Fryer AA, Strange RC. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: Studies in upper aerodigestive tract cancers. Pharmacogenetics. 1998;8:91–100. [PubMed]
  • Moran JL, Siegel D, Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA. 1999;96:8150–8155. [PubMed]
  • Murata M, Shiraishi T, Fukutome K, Watanabe M, Nagao M, Kubota Y, Ito H, Kawamura J, Yatani R. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol. 1998;28:657–660. [PubMed]
  • Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R, Shiraishi T. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett. 2001;165:171–177. [PubMed]
  • Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: A HuGE review. Genet Med. 2002;4:62–70. [PubMed]
  • Nimura Y, Yokoyama S, Fujimori M, Aoki T, Adachi W, Nasu T, He M, Ping YM, Iida F. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer. 1997;80:852–857. [PubMed]
  • Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:185–191. [PubMed]
  • Omiecinski CJ, Hassett C, Hosagrahara V. Epoxide hydrolase—polymorphism and role in toxicology. Toxicol Lett. 2000;112–113:365–370.
  • Palackal NT, Lee SH, Harvey RG, Blair IA, Penning TM. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J Biol Chem. 2002;277:24799–24808. [PubMed]
  • Park JY, Schantz SP, Lazarus P. Epoxide hydrolase genotype and orolaryngeal cancer risk: Interaction with GSTM1 genotype. Oral Oncol. 2003;39:483–490. [PubMed]
  • Park LY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie JP, Jr, Lazarus P. Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics. 2000;10:123–131. [PubMed]
  • Pastorelli R, Guanci M, Cerri A, Negri E, La Vecchia C, Fumagalli F, Mezzetti M, Cappelli R, Panigalli T, Fanelli R, Airoldi L. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiol Biomarkers Prev. 1998;7:703–709. [PubMed]
  • Pelkonen O, Nebert DW. Metabolism of polycyclic aromatic hydrocarbons: Etiologic role in carcinogenesis. Pharmacol Rev. 1982;34:189–222. [PubMed]
  • Peters ES, Kelsey KT, Wiencke JK, Park S, Chen P, Miike R, Wrensch MR. NAT2 and NQO1 polymorphisms are not associated with adult glioma. Cancer Epidemiol Biomarkers Prev. 2001;10:151–152. [PubMed]
  • Phillips LE, Longstreth WT, Jr, Koepsell T, Custer BS, Kukull WA, van Belle G. Active and passive cigarette smoking and risk of intracranial meningioma. Neuroepidemiology. 2005;24:117–122. [PubMed]
  • Preston-Martin S. Descriptive epidemiology of primary tumors of the brain, cranial nerves and cranial meninges in Los Angeles County. Neuroepidemiology. 1989;8:283–295. [PubMed]
  • Raaka S, Hassett C, Omiecinski CJ. Human microsomal epoxide hydrolase: 5‘-flanking region genetic polymorphisms. Carcinogenesis. 1998;19:387–393. [PubMed]
  • Ramsay HM, Harden PN, Reece S, Smith AG, Jones PW, Strange RC, Fryer AA. Polymorphisms in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: A preliminary analysis. J Invest Dermatol. 2001;117:251–255. [PubMed]
  • Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): Chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129:77–97. [PubMed]
  • Sato M, Sato T, Izumo T, Amagasa T. Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol. 2000;36:267–271. [PubMed]
  • Schnakenberg E, Breuer R, Werdin R, Dreikorn K, Schloot W. Susceptibility genes: GSTM1 and GSTM3 as genetic risk factors in bladder cancer. Cytogenet Cell Genet. 2000;91:234–238. [PubMed]
  • Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 1996;56:2979–2984. [PubMed]
  • Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999;20:1607–1613. [PubMed]
  • Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S-transferase family of enzymes. Mutat Res. 2001;482:21–26. [PubMed]
  • Stucker I, Jacquet M, de Waziers I, Cenee S, Beaune P, Kremers P, Hemon D. Relation between inducibility of CYP1A1, GSTM1 and lung cancer in a French population. Pharmacogenetics. 2000;10:617–627. [PubMed]
  • Taioli E, Crofts F, Trachman J, Bayo S, Toniolo P, Garte SJ. Radical differences in CYP1A1 genotype and function. Toxicol Lett. 1995;77:357–362. [PubMed]
  • Thomas TL, Fontham ET, Norman SA, Stemhagen A, Hoover RN. Occupational risk factors for brain tumors. A case-referent death-certificate analysis. Scand J Work Environ Health. 1986;12:121–127. [PubMed]
  • Thomas TL, Stewart PA, Stemhagen A, Correa P, Norman SA, Bleecker ML, Hoover RN. Risk of astrocytic brain tumors associated with occupational chemical exposures. A case-referent study. Scand J Work Environ Health. 1987;13:417–423. [PubMed]
  • Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase) Br J Cancer. 1997;75:69–75. [PMC free article] [PubMed]
  • Trizna Z, de Andrade M, Kyritsis AP, Briggs K, Levin VA, Bruner JM, Wei Q, Bondy ML. Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. Cancer Epidemiol Biomarkers Prev. 1998;7:553–555. [PubMed]
  • Wang AH, Sun CS, Li LS, Huang JY, Chen QS. Relationship of tobacco smoking CYP1A1 GSTM1 gene polymorphism and esophageal cancer in Xi’an. World J Gastroenterol. 2002;8:49–53. [PubMed]
  • Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX. CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: Study of population from a high-incidence area in north China. World J Gastroenterol. 2003;9:1394–1397. [PubMed]
  • Yengi L, Inskip A, Gilford J, Alldersea J, Bailey L, Smith A, Lear JT, Heagerty AH, Bowers B, Hand P, Hayes JD, Jones PW, Strange RC, Fryer AA. Polymorphism at the glutathione S-transferase locus GSTM3: Interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res. 1996;56:1974–1977. [PubMed]
  • Zheng W, Xie DW, Jin F, Cheng JR, Dai Q, Wen WQ, Shu XO, Gao YT. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:147–150. [PubMed]

Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press